Hepatic delivery of RNA interference activators for therapeutic application

Current Gene Therapy

Volumn 9, Issue 2, 2009, Pages 91-103

  Arbuthnot, Patrick ^a   Ely, Abdullah ^a   Weinberg, Marc S ^a  

^a UNIVERSITY OF THE WITWATERSRAND MEDICAL SCHOOL   (South Africa)

Author keywords

Adeno associated virus; Adenovirus; Cirrhosis; HBV; HCV; Liver cancer; Non viral vector; siRNA

Indexed keywords

ADENOVIRUS VECTOR; ALPHA TOCOPHEROL; HEAT SHOCK PROTEIN 47; LENTIVIRUS VECTOR; MICRORNA; PARVOVIRUS VECTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; RETINOL; RNA DERIVATIVE; RNA INTERFERENCE ACTIVATOR; SERINE PROTEINASE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

DISEASE MODEL; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; GENE SILENCING; HEPATITIS B; HEPATITIS C; HUMAN; HYPERCHOLESTEROLEMIA; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; MORBIDITY; MORTALITY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; REVIEW; RNA INTERFERENCE; RNA STRUCTURE; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ADENOVIRIDAE; CARCINOMA, HEPATOCELLULAR; GENE SILENCING; GENETIC VECTORS; HUMANS; HYPERCHOLESTEROLEMIA; LIVER; LIVER DISEASES; LIVER NEOPLASMS; MODELS, BIOLOGICAL; RNA INTERFERENCE;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 65949119980     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652309787909517     Document Type: Review

References (133)

1. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-11.
2. Hawkins PG, Morris KV. RNA and transcriptional modulation of gene expression. Cell Cycle 2008; 7: 602-7.
3. Stefani G, Slack FJ. Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol 2008; 9: 219-30.
4. Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003; 425: 415-9.
5. Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 2004; 10: 1957-66.
6. Denli AM, Tops BB, Plasterk RH, et al. Processing of primary microRNAs by the microprocessor complex. Nature 2004; 432: 231-5.
7. Morlando M, Ballarino M, Gromak N, et al. Primary microRNA transcripts are processed co-transcriptionally. Nat Struct Mol Biol 2008; 15: 902-9.
8. Kim YK, Kim VN. Processing of intronic microRNAs. Embo J 2007; 26: 775-83.
9. Okamura K, Hagen JW, Duan H, et al. The mirtron pathway generates microRNA-class regulatory RNAs in Drosophila. Cell 2007; 130: 89-100.
10. Ruby JG, Jan CH, Bartel DP. Intronic microRNA precursors that bypass Drosha processing. Nature 2007; 448: 83-6.
11. Yi R, Qin Y, Macara IG, et al. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003; 17: 3011-6.
12. Lund E, Guttinger S, Calado A, et al. Nuclear export of microRNA precursors. Science 2004; 303: 95-8.
13. Bernstein E, Caudy AA, Hammond SM, et al. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001; 409: 363-6.
14. Hutvagner G, McLachlan J, Pasquinelli AE, et al. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 2001; 293: 834-8.
15. Chendrimada TP, Gregory RI, Kumaraswamy E, et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 2005; 436: 740-4.
16. Liu J, Carmell MA, Rivas FV, et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 2004; 305: 1437-41.
17. MacRae IJ, Ma E, Zhou M, et al. In vitro reconstitution of the human RISC-loading complex. Proc Natl Acad Sci USA 2008; 105: 512-7.
18. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003; 115: 209-16.
19. Hutvagner G, Simard MJ. Argonaute proteins: key players in RNA silencing. Nat Rev Mol Cell Biol 2008; 9: 22-32.
20. Rana TM. Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 2007; 8: 23-36.
21. Lewis BP, Shih IH, Jones-Rhoades MW, et al. Prediction of mammalian microRNA targets. Cell 2003; 115: 787-98.
22. Shiba Y, Masuda H, Watanabe N, et al. Chemical synthesis of a very long oligoribonucleotide with 2-cyanoethoxymethyl (CEM) as the 2'-O-protecting group: structural identification and biological activity of a synthetic 110mer precursor-microRNA candidate. Nucleic Acids Res 2007; 35: 3287-96.
23. Behlke MA. Progress towards in vivo use of siRNAs. Mol Ther 2006; 13: 644-70.
24. Behlke MA. Chemical modification of siRNAs for in vivo use. Oligonucleotides 2008; 18: 305-19.
25. Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005; 23: 1002-7.
26. Muhonen P, Tennila T, Azhayeva E, et al. RNA interference tolerates 2′-fluoro modifications at the Argonaute2 cleavage site. Chem Biodivers 2007; 4: 858-73.
27. Robbins M, Judge A, Liang L, et al. 2′-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther 2007; 15: 1663-9.
28. Chen PY, Weinmann L, Gaidatzis D, et al. Strand-specific 5′-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA 2008; 14: 263-74.
29. Mook OR, Baas F, de Wissel MB, et al. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol Cancer Ther 2007; 6: 833-43.
30. Jackson AL, Burchard J, Leake D, et al. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 2006; 12: 1197-205.
31. Swayze EE, Siwkowski AM, Wancewicz EV, et al. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res 2007; 35: 687-700.
32. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432: 173-8.
33. Lorenz C, Hadwiger P, John M, et al. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett 2004; 14: 4975-7.
34. Nishina K, Unno T, Uno Y, et al. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol Ther 2008; 16: 734-40.
35. Weinberg MS, Ely A, Barichievy S, et al. Specific inhibition of HBV replication in vitro and in vivo with expressed long hairpin RNA. Mol Ther 2007; 15: 534-41.
36. Akashi H, Miyagishi M, Yokota T, et al. Escape from the interferon response associated with RNA interference using vectors that encode long modified hairpin-RNA. Mol BioSyst 2005; 1: 382-90.
37. Watanabe T, Sudoh M, Miyagishi M, et al. Intracellular-diced dsRNA has enhanced efficacy for silencing HCV RNA and overcomes variation in the viral genotype. Gene Ther 2006; 13: 883-92.
38. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441: 537-41.
39. Miyagishi M, Taira K. RNAi expression vectors in mammalian cells. Methods Mol Biol 2004; 252: 483-91.
40. Ely A, Naidoo T, Mufamadi S, et al. Expressed anti-HBV primary microRNA shuttles inhibit viral replication efficiently in vitro and in vivo. Mol Ther 2008; 16: 1105-12.
41. Liu YP, Haasnoot J, ter Brake O, et al. Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res 2008; 36: 2811-24.
42. Li L, Lin X, Khvorova A, et al. Defining the optimal parameters for hairpin-based knockdown constructs. RNA 2007; 13: 1765-74.
43. Bangari DS, Mittal SK. Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther 2006; 6: 215-26.
44. Alemany R, Curiel DT. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther 2001; 8: 1347-53.
45. Smith TA, Idamakanti N, Marshall-Neff J, et al. Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. Hum Gene Ther 2003; 14: 1595-604.
46. Waddington SN, McVey JH, Bhella D, et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008; 132: 397-409.
47. Schaack J. Adenovirus vectors deleted for genes essential for viral DNA replication. Front Biosci 2005; 10: 1146-55.
48. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-58.
49. Zhang Y, Chirmule N, Gao GP, et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 2001; 3: 697-707.
50. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19: 65-91.
51. Kreppel F, Kochanek S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther 2008; 16: 16-29.
52. Crowther C, Ely A, Hornby J, et al. Efficient inhibition of hepatitis B virus replication in vivo using peg-modified adenovirus vectors. Hum Gene Ther 2008. [Epub ahead of print]
53. Schnell MA, Zhang Y, Tazelaar J, et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther 2001; 3: 708-22.
54. Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 2008; 21: 583-93.
55. Schultz BR, Chamberlain JS. Recombinant adeno-associated virus transduction and integration. Mol Ther 2008; 16: 1189-99.
56. Buning H, Perabo L, Coutelle O, et al. Recent developments in adeno-associated virus vector technology. J Gene Med 2008; 10: 717-33.
57. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 2004; 72: 1438-45.
58. Blouin V, Brument N, Toublanc E, et al. Improving rAAV production and purification: towards the definition of a scaleable process. J Gene Med 2004; 6(Suppl 1): S223-8.
59. Urabe M, Ding C, Kotin RM. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther 2002; 13: 1935-43.
60. McCaffrey AP, Fawcett P, Nakai H, et al. The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver. Mol Ther 2008; 16: 931-41.
61. Singer O, Verma IM. Applications of lentiviral vectors for shRNA delivery and transgenesis. Curr Gene Ther 2008; 8: 483-8.
62. Breckpot K, Emeagi PU, Thielemans K. Lentiviral vectors for antitumor immunotherapy. Curr Gene Ther 2008; 8: 438-48.
63. Ciuffi A. Mechanisms governing lentivirus integration site selection. Curr Gene Ther 2008; 8: 419-29.
64. Frecha C, Szecsi J, Cosset FL, et al. Strategies for targeting lentiviral vectors. Curr Gene Ther 2008; 8: 449-60.
65. Lundberg C, Bjorklund T, Carlsson T, et al. Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Curr Gene Ther 2008; 8: 461-73.
66. Sarkis C, Philippe S, Mallet J, et al. Non-integrating lentiviral vectors. Curr Gene Ther 2008; 8: 430-7.
67. Schambach A, Baum C. Clinical application of lentiviral vectors - concepts and practice. Curr Gene Ther 2008; 8: 474-82.
68. Valori CF, Ning K, Wyles M, et al. Development and applications of non-HIV-based lentiviral vectors in neurological disorders. Curr Gene Ther 2008; 8: 406-18.
69. Park F, Ohashi K, Chiu W, et al. Efficient lentiviral transduction of liver requires cell cycling in vivo. Nat Genet 2000; 24: 49-52.
70. Chen Y, Lin MC, Yao H, et al. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology 2007; 46: 200-8.
71. Yang Q, Lucas A, Son S, et al. Overlapping enhancer/promoter and transcriptional termination signals in the lentiviral long terminal repeat. Retrovirology 2007; 4: 4.
72. Zaiss AK, Son S, Chang LJ. RNA 3′ readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy. J Virol 2002; 76: 7209-19.
73. Hargrove PW, Kepes S, Hanawa H, et al. Globin lentiviral vector insertions can perturb the expression of endogenous genes in beta-thalassemic hematopoietic cells. Mol Ther 2008; 16: 525-33.
74. Flowers CC, Woffendin C, Petryniak J, et al. Inhibition of recombinant human immunodeficiency virus type 1 replication by a site-specific recombinase. J Virol 1997; 71: 2685-92.
75. Tiscornia G, Singer O, Verma IM. Design and cloning of lentiviral vectors expressing small interfering RNAs. Nat Protoc 2006; 1: 234-40.
76. Ventura A, Meissner A, Dillon CP, et al. Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci USA 2004; 101: 10380-5.
77. Tiscornia G, Tergaonkar V, Galimi F, et al. CRE recombinase-inducible RNA interference mediated by lentiviral vectors. Proc Natl Acad Sci USA 2004; 101: 7347-51.
78. Barteau B, Chevre R, Letrou-Bonneval E, et al. Physicochemical parameters of non-viral vectors that govern transfection efficiency. Curr Gene Ther 2008; 8: 313-23.
79. Braun S. Muscular gene transfer using nonviral vectors. Curr Gene Ther 2008; 8: 391-405.
80. Harraghy N, Gaussin A, Mermod N. Sustained transgene expression using MAR elements. Curr Gene Ther 2008; 8: 353-66.
81. Midoux P, Breuzard G, Gomez JP, et al. Polymer-based gene delivery: a current review on the uptake and intracellular trafficking of polyplexes. Curr Gene Ther 2008; 8: 335-52.
82. Montier T, Benvegnu T, Jaffres PA, et al. Progress in cationic lipid-mediated gene transfection: a series of bio-inspired lipids as an example. Curr Gene Ther 2008; 8: 296-312.
83. Palazzoli F, Carnus E, Wells DJ, et al. Sustained transgene expression using non-viral enzymatic systems for stable chromosomal integration. Curr Gene Ther 2008; 8: 367-90.
84. Philipp A, Meyer M, Wagner E. Extracellular targeting of synthetic therapeutic nucleic acid formulations. Curr Gene Ther 2008; 8: 324-34.
85. Pitard B. Convergence of opposite sciences for the future development of non viral gene therapy. Curr Gene Ther 2008; 8: 295.
86. Wu GY, Wu CH. Receptor-mediated gene delivery and expression in vivo. J Biol Chem 1988; 263: 14621-4.
87. Ahmad A, Evans HM, Ewert K, et al. New multivalent cationic lipids reveal bell curve for transfection efficiency versus membrane charge density: lipid-DNA complexes for gene delivery. J Gene Med 2005; 7: 739-48.
88. Farago O, Ewert K, Ahmad A, et al. Transitions between distinct compaction regimes in complexes of multivalent cationic lipids and DNA. Biophys J 2008; 95: 836846.
89. Akinc A, Zumbuehl A, Goldberg M, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008; 26: 561-9.
90. Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 2008; 105: 11915-20.
91. Spagnou S, Miller AD, Keller M. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 2004; 43: 13348-56.
92. Kim SI, Shin D, Choi TH, et al. Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I. Mol Ther 2008; 15: 1145-52.
93. Sato Y, Murase K, Kato J, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol 2008; 26: 431-42.
94. Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006; 441: 111-4.
95. Arbuthnot P, Kew M. Hepatitis B virus and hepatocellular carcinoma. Int J Exp Pathol 2001; 82: 77-100.
96. Ferir G, Kaptein S, Neyts J, et al. Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future. Rev Med Virol 2008; 18: 19-34.
97. Keeffe EB, Dieterich DT, Pawlotsky JM, et al. Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol 2008; 6: 268-74.
98. Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature 1985; 317: 489-95.
99. McCaffrey AP, Nakai H, Pandey K, et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003; 21: 639-44.
100. Arbuthnot P, Thompson LJ. Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma. World J Gastroenterol 2008; 14: 1670-81.
101. Yang PL, Althage A, Chung J, et al. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci USA 2002; 99: 13825-30.
102. Carmona S, Ely A, Crowther C, et al. Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs. Mol Ther 2006; 13: 411-21.
103. Uprichard SL, Boyd B, Althage A, et al. Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc Natl Acad Sci USA 2005; 102: 773-8.
104. Rauschhuber C, Xu H, Salazar FH, et al. Exploring gene-deleted adenoviral vectors for delivery of short hairpin RNAs and reduction of hepatitis B virus infection in mice. J Gene Med 2008; 10: 878-89.
105. Chen CC, Ko TM, Ma HI, et al. Long-term inhibition of hepatitis B virus in transgenic mice by double-stranded adeno-associated virus 8-delivered short hairpin RNA. Gene Ther 2007; 14: 11-9.
106. Chen CC, Sun CP, Ma HI, et al. Comparative study of antihepatitis B virus RNA interference by double-stranded adeno-associated virus serotypes 7, 8, and 9. Mol Ther 2009; 17: 352-59.
107. Carmona S, Keller M, Jorgensen MR, et al. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. Mol Pharm 2008. in press.
108. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20: 1-16.
109. Bartenschlager R, Frese M, Pietschmann T. Novel insights into hepatitis C virus replication and persistence. Adv Virus Res 2004; 63: 71-180.
110. Kronke J, Kittler R, Buchholz F, et al. Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs. J Virol 2004; 78: 3436-46.
111. Randall G, Rice CM. Interfering with hepatitis C virus RNA replication. Virus Res 2004; 102: 19-25.
112. Takigawa Y, Nagano-Fujii M, Deng L, et al. Suppression of hepatitis C virus replicon by RNA interference directed against the NS3 and NS5B regions of the viral genome. Microbiol Immunol 2004; 48: 591-8.
113. Wang Q, Contag CH, Ilves H, et al. Small hairpin RNAs efficiently inhibit hepatitis C IRES-mediated gene expression in human tissue culture cells and a mouse model. Mol Ther 2005; 12: 562-8.
114. Yokota T, Sakamoto N, Enomoto N, et al. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO 2003; Rep 4: 602-8.
115. Zhang J, Yamada O, Sakamoto T, et al. Down-regulation of viral replication by adenoviral-mediated expression of siRNA against cellular cofactors for hepatitis C virus. Virology 320: 135-43.
116. Domitrovich AM, Diebel KW, Ali N, et al. Role of La autoantigen and polypyrimidine tract-binding protein in HCV replication. Virology 2005; 335: 72-86.
117. Nakagawa M, Sakamoto N, Tanabe Y, et al. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology 2005; 129: 1031-41.
118. Jopling CL, Yi M, Lancaster AM, et al. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 2005; 309: 1577-81.
119. Shan Y, Zheng J, Lambrecht RW, et al. Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology 2007; 133: 1166-74.
120. Henke JI, Goergen D, Zheng J, et al. MicroRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J 2008; 27: 3300-10.
121. Dimitrova M, Affolter C, Meyer F, et al. Sustained delivery of siRNAs targeting viral infection by cell-degradable multilayered polyelectrolyte films. Proc Natl Acad Sci USA 2008; 105: 16320-5.
122. Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol 2005; 79: 9369-80.
123. Mercer DF, Schiller DE, Elliott JF, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927-933.
124. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
125. Cho-Rok J, Yoo J, Jang YJ, et al. Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology 2006; 43: 1042-52.
126. Salvi A, Arici B, Alghisi A, et al. RNA interference against urokinase in hepatocellular carcinoma xenografts in nude mice. Tumour Biol 2007; 28: 16-26.
127. Salvi A, Arici B, De Petro G, et al. Small interfering RNA urokinase silencing inhibits invasion and migration of human hepatocellular carcinoma cells. Mol Cancer Ther 2004; 3: 671-78.
128. Li H, Fu X, Chen Y, et al. Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma. Gastroenterology 2005; 128: 2029-41.
129. Chen Y, Lin MC, Wang H, et al. Proteomic analysis of EZH2 downstream target proteins in hepatocellular carcinoma. Proteomics 2007; 7: 3097-104.
130. Bhatnagar D, Soran H, Durrington PN. Hypercholesterolaemia and its management. BMJ 2008; 337: a993.
131. Rashid S, Curtis DE, Garuti R, et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci USA 2005; 102: 5374-9.
132. Cohen JC, Boerwinkle E, Mosley TH, Jr., et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264-72.
133. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-50.